<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T05:53:16Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/223860" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/223860</identifier><datestamp>2025-12-02T07:01:21Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478858</setSpec><setSpec>col_2072_478917</setSpec><setSpec>col_2072_478921</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Thinner and wiser? Prospects of GLP-1 agonists in psychiatry</dc:title>
   <dc:creator>Vieta i Pascual, Eduard, 1963-</dc:creator>
   <dc:creator>Oliva, Vincenzo</dc:creator>
   <dc:subject>Malalties mentals</dc:subject>
   <dc:subject>Cognició</dc:subject>
   <dc:subject>Hormones gastrointestinals</dc:subject>
   <dc:subject>Humor (Psicologia)</dc:subject>
   <dc:subject>Psiquiatria</dc:subject>
   <dc:subject>Mental illness</dc:subject>
   <dc:subject>Cognition</dc:subject>
   <dc:subject>Gastrointestinal hormones</dc:subject>
   <dc:subject>Mood (Psychology)</dc:subject>
   <dc:subject>Psychiatry</dc:subject>
   <dc:description>In recent years, growing scientific attention has converged on the intricate, bidirectional relationship between physical health and mental well-being. Chronic inflammation, disruptions in the gut–brain axis and microbiota, and metabolic alterations such as obesity and type 2 diabetes have all been implicated in the pathophysiology of neuropsychiatric disorders. These insights are not merely academic—they are transforming how we approach, frame, and treat neuropsychiatric disorders.</dc:description>
   <dc:date>2025-10-23T15:47:35Z</dc:date>
   <dc:date>2025-05-22</dc:date>
   <dc:date>2025-10-23T15:47:35Z</dc:date>
   <dc:date>info:eu-repo/date/embargoEnd/2026-05-21</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
   <dc:identifier>0924-977X</dc:identifier>
   <dc:identifier>https://hdl.handle.net/2445/223860</dc:identifier>
   <dc:identifier>759656</dc:identifier>
   <dc:identifier>40409236</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Versió postprint del document publicat a: https://doi.org/10.1016/j.euroneuro.2025.05.006</dc:relation>
   <dc:relation>European Neuropsychopharmacology, 2025, vol. 97, p. 3-4</dc:relation>
   <dc:relation>https://doi.org/10.1016/j.euroneuro.2025.05.006</dc:relation>
   <dc:rights>cc-by-nc-nd (c) Elsevier B.V., 2025</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/embargoedAccess</dc:rights>
   <dc:format>7 p.</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Elsevier B.V.</dc:publisher>
   <dc:source>Articles publicats en revistes (Medicina)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>